Craft

Allakos

Stock Price

$1.2

2024-05-03

Market Capitalization

$102.7 M

2024-05-03

Allakos Summary

Company Summary

Overview
Allakos, a biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The Company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Type
Public
Status
Active
Founded
2012
HQ
Redwood City, CA, US | view all locations
Website
https://www.allakos.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Dan Janney, Chairman

    • Robert Alexander, Chief Executive Officer

      • Robert Andreatta
      • Paul Walker, Director

        LocationsView all

        2 locations detected

        • Redwood City, CA HQ

          United States

          975 Island Dr #201

        • San Carlos, CA

          United States

          825 Industrial Rd #500

        Allakos Financials

        Summary Financials

        Net income (FY, 2023)
        ($185.7M)
        Cash (FY, 2023)
        $66.4M
        EBIT (FY, 2023)
        ($196.1M)

        Footer menu